CMS Advisory Panel Provides Some Potential Good News For Glaukos

Rate adjustment recommendations to US Medicare could result in less drastic reimbursement cuts for Glaukos than those currently on the table.

US MEDICARE AND COINS.
• Source: Alamy

It's not been an ideal summer for the Glaukos Corporation, which took a couple of significant blows in July when the US Centers for Medicare & Medicaid Services (CMS) recommended cuts to reimbursement for the company’s iStent device used in cataract surgeries.

First, in its 13 July Physician Fee Schedule (PFS), CMS proposed combining the cataract surgery and stent placement codes –...

More from Policy & Regulation

More from Medtech Insight